Analysts’ Opinions Are Mixed on These Healthcare Stocks: Quest Diagnostics Inc. (NYSE: DGX) and Esperion (NASDAQ: ESPR)

By Ryan Adsit

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quest Diagnostics Inc. (NYSE: DGX) and Esperion (NASDAQ: ESPR).

Quest Diagnostics Inc. (NYSE: DGX)

Quest Diagnostics Inc. (NYSE: DGX) received a Buy rating from UBS analyst A.J. Rice today. The company’s shares closed last Friday at $81.46.

According to TipRanks.com, Rice is ranked 0 out of 5 stars with an average return of -7.2% and a 40.0% success rate. Rice covers the Healthcare sector, focusing on stocks such as Envision Healthcare, Kindred Healthcare, and Genesis Healthcare.

Quest Diagnostics Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $87.

Esperion (NASDAQ: ESPR)

Citigroup analyst Joel Beatty downgraded Esperion (NASDAQ: ESPR) to Hold today. The company’s shares closed last Friday at $11.99, close to its 52-week low of $9.40.

According to TipRanks.com, Beatty is ranked 0 out of 5 stars with an average return of -12.7% and a 21.1% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Dimension Therapeutics Inc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $19.50.